A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
| 대상 질환 | Ulcerative Colitis, Ulcerative Colitis Chronic |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | Eli Lilly and Company |
| 상태 | 완료 |
| 참여자 수 | 172 명 |
| 중재(약물) | Mirikizumab, Mirikizumab |
| 시작일 | 2023년 5월 17일 |
| 완료일 | 2024년 8월 9일 |
| 결과 공개일 | 2025년 9월 30일 |
요약
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Change From Baseline in Bowel Urgency Severity Urgency Numeric Rating Scale (UNRS)
| 300 mg Mirikizumab | -3.25 score on a scale |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
- GI Permeability Change in Response to Aquamin® — James Varani
- A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
- Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University